Skip to main content
letter
. 2022 May 1;24(7):1380–1384. doi: 10.1111/dom.14681

TABLE 2.

Characteristics at the time of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) prescription a

Overall (n = 54) After the first year of T2D diagnosis (n = 26) Within the first year of T2D diagnosis (n = 28) Estimated contrast between prescribing groups b (95% CI)
Age (y) 14.8 (1.9) 15.2 (1.9) 14.5 (1.9) −0.69 (−1.73, 0.35)
BMI (kg/m2) 37.9 (7.7) 37.5 (6.3) 38.3 (8.8) 0.79 (−3.43, 5.01)
BMI percentage of the 95th percentile 137 (26.9) 134 (24.4) 140 (29.3) 5.68 (−9.11, 20.47)
HbA1c (%) 9.4 (2.8) 10.4 (2.8) 8.5 (2.4) −1.83 (−3.28, −0.39)*
Male sex (%) 26 (48.1) 11 (42.3) 15 (53.6) 1.57 (0.54, 4.61)
Race/ethnicity (%)
African American/Black 17 (31.5) 10 (38.5) 7 (25.0) Reference
White, non‐Hispanic 10 (18.5) 4 (15.4) 6 (21.4) 2.14 (0.44, 10.53)
White, Hispanic 9 (16.7) 4 (15.4) 5 (17.9) 1.79 (0.35, 9.13)
Asian 6 (11.1) 4 (15.4) 2 (7.1) 0.71 (0.10, 5.04)
Multiple 4 (7.4) 1 (3.8) 3 (10.7) 4.29 (0.37, 50.21)
Native American 3 (3.0) 2 (2.8) 1 (3.6) 1.79 (0.14, 22.70)
Missing 6 (11.1) 2 (7.7) 4 (14.3)
Concomitant insulin (%) 36 (66.7) 21 (80.8) 15 (53.6) 0.27 (0.08, 094)*
Long‐acting insulin dose (units/kg/d) 0.42 (0.32) 0.5 (0.38) 0.32 (0.15) −0.18 (−0.39, 0.03)
Concomitant weight‐loss medications (%)
Stimulants 9 (16.7) 5 (19.2) 4 (14.3) 0.73 (0.17, 3.09)
Topiramate 8 (14.8) 3 (11.5) 5 (17.9) 1.67 (0.36, 7.80)
Bupropion 5 (9.3) 3 (11.5) 2 (7.1) 0.59 (0.09, 3.85)
Naltrexone 2 (3.7) 0 (0.0) 2 (7.1) N/A
Concomitant diabetes medications (%)
Metformin 45 (83.3) 22 (84.6) 23 (82.1) 0.84 (0.20, 3.53)
DPP‐IV inhibitors 4 (7.4) 1 (3.8) 3 (10.7) 3.00 (0.29, 30.84)
SGLT‐2 inhibitors 10 (18.5) 2 (7.7) 8 (28.6) 4.80 (0.91, 25.23)
Sulphonylureas 3 (5.6) 1 (3.8) 2 (7.1) 1.92 (0.16, 22.56)

Abbreviations: BMI, body mass index; DPP‐IV, dipeptidyl peptidase‐IV; SGLT‐2, sodium‐glucose co‐transporter‐2; T2D, type 2 diabetes.

a

Continuous variables are described as value (SD). Categorical variables are described as n (%).

b

Estimates are mean differences or odds ratios.

*

P < .05.

HHS Vulnerability Disclosure